Lantheus (LNTH)
(Delayed Data from NSDQ)
$100.60 USD
-1.38 (-1.35%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $100.62 +0.02 (0.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
LNTH 100.60 -1.38(-1.35%)
Will LNTH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LNTH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LNTH
Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now?
Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?
LNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Investors Must Hold on to Centene (CNC) Stock Now
Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term
Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term
Other News for LNTH
Perspective gets FDA fast track status for radiopharmaceutical VMT01
Perspective gets FDA fast track status for radiopharmaceutical VMT101
Lantheus Bolsters Board with Expert Finance Executive
Lantheus appoints Eastland as new board member
Novartis expands U.S. radiopharma production amid rising competition